BioPharma Dive - Latest News

Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

May 20, 2025 - 17:30
 0
Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff

Tourmaline Bio disclosed results for a potential rival to a Novo Nordisk drug. Elsewhere, data emerged for a psychedelic and CRISPR Therapeutics expanded its toolkit.

Read More

Tags:

Previous Article

FDA sets stricter approval standards for COVID vaccines

Next Article

STAT+: Access to diabetes care in lower-income countries still lags for children...

Related Posts

FDA OKs first blood test to aid Alzheimer’s diagnosis

FDA OKs first blood test to aid Alzheimer’s diagnosis

May 19, 2025  0

A bespoke CRISPR therapy suggests a blueprint for treating ‘N-of-1’ diseases

A bespoke CRISPR therapy suggests a blueprint for treat...

May 15, 2025  0

5 questions on Trump’s plan to lower US drug prices

5 questions on Trump’s plan to lower US drug prices

May 13, 2025  0